Brainomix Extends Series C Financing to $25.4M to Support U.S. Expansion

Brainomix United States of America England United Kingdom

is a leading Australian industry superannuation (pension) fund with over AUD$140 billion in funds under management. Modi Ventures is an early-stage US-based venture capital firm investing in health tech, tech bio, and artificial intelligence.

About Brainomix

Brainomix is a global pioneer in AI medical imaging, enabling precision medicine for better treatment decisions in stroke and lung fibrosis. Its flagship product, Brainomix 360 Stroke, is the world's first fully automated AI-imaging platform, designed for acute stroke assessment at all points of the patient pathway, facilitating more confident treatment and transfer decisions for patients in all hospitals, regardless of local resources or expertise. Brainomix 360 e-Lung technology applies AI-driven CT biomarkers to identify, monitor, and predict disease progression in pulmonary fibrosis. Founded as a spinout from the?University of?Oxford, Brainomix has offices in the UK,?Ireland?and the?USA, and operations in more than 20 countries.

To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, LinkedIn and Facebook.

Contacts
Jeff Wyrtzen, Chief Marketing Officer
[e-mail]
T [phone]

US Media Enquiries
Jason Braco, Ph.D.
LifeSci Communications
[e-mail]

UK & Europe Media Enquiries
Sue Charles 
Charles Consultants
[e-mail] 

 

Photo - https://mma.prnewswire.com/media/2918294/Brainomix_CEO.jpg
Photo - https://mma.prnewswire.com/media/2918295/Brainomix_360_Stroke.jpg
Logo - https://mma.prnewswire.com/media/1989193/5818779/Brainomix_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/brainomix-extends-series-c-financing-to-25-4m-18-8m-to-support-us-expansion-302695050.html